



NDA 18-584/S-026

GlaxoSmithKline
Five Moore Drive
PO Box 13398
Research Triangle Park NC 27709-3398

Attention: Alison Bowers
Product Director
Regulatory Affairs

Dear Ms. Bowers:

Please refer to your supplemental new drug application dated April 17, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Beconase (beclomethasone dpropionate) Nasal Aerosol.

We acknowledge receipt of your submissions dated January 5, 1999, and November 21, 2000.

Your submission of November 21, 2000, constituted a complete response to our August 25, 2000, action letter.

This supplemental new drug application provides for revisions to the PRECAUTIONS, and ADVERSE REACTIONS sections of the package inserts to include information on the growth suppressive effects of inhaled corticosteroids

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (package insert submitted November 21, 2000).

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 18-584/S-026. Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2

FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Ms. Ladan Jafari, Regulatory Project Manager, at (301) 827-1084.

Sincerely,

{See appended electronic signature page}

Badrul A. Chowdhury, M.D., Ph.D.
Acting Director
Division of Pulmonary and Allergy Drug Product
Office of Drug Evaluation II
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Badrul Chowdhury
12/16/02 04:49:33 PM